Pharmacological Cardioprotection against Ischemia Reperfusion Injury—The Search for a Clinical Effective Therapy
Cells · 20.05.2023 · 12 (10) · 1432
DOI: 10.3390/cells12101432 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 20.05.2023. Verfasst von Qian Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology-L.E.I.C.A., Amsterdam University Medical Centers, Location AMC, Cardiovascular Science, Meibergdreef 11, 1105 AZ Amsterd…. Hauptthemen laut MEDLINE: Mitochondrial Membrane Transport Proteins, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 257 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Scholarship Council, Dutch Research Council.
Abstract (Originalsprache)
Pharmacological conditioning aims to protect the heart from myocardial ischemia-reperfusion injury (IRI). Despite extensive research in this area, today, a significant gap remains between experimental findings and clinical practice. This review provides an update on recent developments in pharmacological conditioning in the experimental setting and summarizes the clinical evidence of these cardioprotective strategies in the perioperative setting. We start describing the crucial cellular processes during ischemia and reperfusion that drive acute IRI through changes in critical compounds (∆GATP, Na+, Ca2+, pH, glycogen, succinate, glucose-6-phosphate, mitoHKII, acylcarnitines, BH4, and NAD+). These compounds all precipitate common end-effector mechanisms of IRI, such as reactive oxygen species (ROS) generation, Ca2+ overload, and mitochondrial permeability transition pore opening (mPTP). We further discuss novel promising interventions targeting these processes, with emphasis on cardiomyocytes and the endothelium. The limited translatability from basic research to clinical practice is likely due to the lack of comorbidities, comedications, and peri-operative treatments in preclinical animal models, employing only monotherapy/monointervention, and the use of no-flow (always in preclinical models) versus low-flow ischemia (often in humans). Future research should focus on improved matching between preclinical models and clinical reality, and on aligning multitarget therapy with optimized dosing and timing towards the human condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology-L.E.I.C.A., Amsterdam University Medical Centers, Location AMC, Cardiovascular Science, Meibergdreef 11, 1105 AZ Amsterdam, The Netherlands.
- Department of Anesthesiology, Kerckhoff-Clinic-Center for Heart, Lung, Vascular and Rheumatic Disease, Justus-Liebig-University Giessen, Benekestr. 2-8, 61231 Bad Nauheim, Germany.
ORCID-Profile: Coert J Zuurbier, Markus W Hollmann, Benedikt Preckel, Charissa E van den Brom, Nina C Weber
Förderung
- Chinese Scholarship Council
- Dutch Research Council
Zitieren
APA
Wang, Q., Zuurbier, C. J., Huhn, R., Torregroza, C., Hollmann, M. W., Preckel, B., van den Brom, C. E., & Weber, N. C. (2023). Pharmacological Cardioprotection against Ischemia Reperfusion Injury—The Search for a Clinical Effective Therapy. Cells, 12(10), 1432. https://doi.org/10.3390/cells12101432
Vancouver
Wang Q, Zuurbier CJ, Huhn R, Torregroza C, Hollmann MW, Preckel B, et al. Pharmacological Cardioprotection against Ischemia Reperfusion Injury—The Search for a Clinical Effective Therapy. Cells. 2023;12(10):1432. doi:10.3390/cells12101432
BibTeX
@article{Wang2023,
author = {Wang, Qian and Zuurbier, Coert J and Huhn, Ragnar and Torregroza, Carolin and Hollmann, Markus W and Preckel, Benedikt and van den Brom, Charissa E and Weber, Nina C},
title = {Pharmacological Cardioprotection against Ischemia Reperfusion Injury—The Search for a Clinical Effective Therapy},
journal = {Cells},
year = {2023},
volume = {12},
number = {10},
pages = {1432},
doi = {10.3390/cells12101432}
}
EUVIMED